87.12
price up icon0.79%   0.68
after-market 시간 외 거래: 91.47 4.35 +4.99%
loading
전일 마감가:
$86.44
열려 있는:
$80.22
하루 거래량:
2.33M
Relative Volume:
4.66
시가총액:
$4.65B
수익:
$144.75M
순이익/손실:
$-53.89M
주가수익비율:
-22.00
EPS:
-3.96
순현금흐름:
$-42.88M
1주 성능:
-0.15%
1개월 성능:
+11.36%
6개월 성능:
+65.34%
1년 성능:
+95.21%
1일 변동 폭
Value
$77.00
$87.74
1주일 범위
Value
$77.00
$91.20
52주 변동 폭
Value
$43.50
$97.54

Arcellx Inc Stock (ACLX) Company Profile

Name
명칭
Arcellx Inc
Name
전화
240-327-0603
Name
주소
800 BRIDGE PARKWAY, REDWOOD CITY
Name
직원
130
Name
트위터
Name
다음 수익 날짜
Name
최신 SEC 제출 서류
Name
ACLX's Discussions on Twitter

Arcellx Inc Stock (ACLX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-01-04 재확인 Needham Buy
2023-12-19 개시 Scotiabank Sector Outperform
2023-10-30 개시 TD Cowen Outperform
2023-10-17 개시 UBS Buy
2023-05-18 개시 Truist Buy
2023-04-14 개시 Robert W. Baird Outperform
2023-03-14 개시 Stifel Buy
2023-02-13 개시 H.C. Wainwright Buy
2022-12-13 재개 BofA Securities Buy
2022-10-31 개시 Guggenheim Buy
2022-10-27 개시 Needham Buy
2022-07-20 개시 Canaccord Genuity Buy
2022-03-01 개시 BofA Securities Buy
2022-03-01 개시 SVB Leerink Outperform
모두보기

Arcellx Inc 주식(ACLX)의 최신 뉴스

pulisher
03:28 AM

BofA raises Arcellx price target to $100 on positive data - Investing.com

03:28 AM
pulisher
02:36 AM

Arcellx (NASDAQ:ACLX) Shares Gap DownHere's Why - MarketBeat

02:36 AM
pulisher
09:53 AM

Arcellx issues updates on anito-cel clinical trials (NASDAQ:ACLX) - Seeking Alpha

09:53 AM
pulisher
09:50 AM

Mirae Asset Global Investments Co. Ltd. Acquires 347 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World

09:50 AM
pulisher
09:35 AM

Arcellx : to Present Clinical Data for Its Phase 1 and iMMagine 1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine 3 Study Form 8 K - Marketscreener.com

09:35 AM
pulisher
09:20 AM

Arcellx reports promising results for myeloma treatment - Investing.com

09:20 AM
pulisher
09:17 AM

Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study - Marketscreener.com

09:17 AM
pulisher
09:00 AM

Arcellx's Multiple Myeloma Drug Shows 95% Response Rate in Phase 2 Trial, Strong Safety Data | ACLX Stock News - StockTitan

09:00 AM
pulisher
07:19 AM

Cancer cell therapy from Arcellx, Gilead shows promise in early data - Yahoo Finance

07:19 AM
pulisher
05:22 AM

Arcellx, Inc. (NASDAQ:ACLX) Shares Purchased by Harbor Capital Advisors Inc. - MarketBeat

05:22 AM
pulisher
Nov 04, 2024

abrdn plc Takes Position in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat

Nov 04, 2024
pulisher
Nov 02, 2024

Arcellx, Inc. (NASDAQ:ACLX) Shares Sold by Allspring Global Investments Holdings LLC - MarketBeat

Nov 02, 2024
pulisher
Nov 02, 2024

Arcellx (NASDAQ:ACLX) Earns “Buy” Rating from Needham & Company LLC - Defense World

Nov 02, 2024
pulisher
Oct 31, 2024

Arcellx (ACLX) Surged in Q3. Here’s Why - Insider Monkey

Oct 31, 2024
pulisher
Oct 31, 2024

Arcellx (NASDAQ:ACLX) Receives Buy Rating from Needham & Company LLC - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Short Interest in Arcellx, Inc. (NASDAQ:ACLX) Expands By 5.3% - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Short Interest in Arcellx, Inc. (NASDAQ:ACLX) Increases By 5.3% - Defense World

Oct 31, 2024
pulisher
Oct 29, 2024

Arcellx shares target increased, Outperform upheld as ASH data release nears - Investing.com India

Oct 29, 2024
pulisher
Oct 28, 2024

A Look At The Fair Value Of Arcellx, Inc. (NASDAQ:ACLX) - Simply Wall St

Oct 28, 2024
pulisher
Oct 24, 2024

Arcellx's SWOT analysis: cell therapy innovator's stock poised for growth By Investing.com - Investing.com Australia

Oct 24, 2024
pulisher
Oct 24, 2024

Gilead needs a win with Arcellx CAR-T data. Here’s how to know if it scores - STAT

Oct 24, 2024
pulisher
Oct 23, 2024

Arcellx's SWOT analysis: cell therapy innovator's stock poised for growth - Investing.com India

Oct 23, 2024
pulisher
Oct 22, 2024

Arcellx director Kavita Patel sells $134,535 in stock - Investing.com

Oct 22, 2024
pulisher
Oct 22, 2024

Arcellx, Inc. (NASDAQ:ACLX) Director Sells $134,535.00 in Stock - MarketBeat

Oct 22, 2024
pulisher
Oct 22, 2024

Arcellx director Kavita Patel sells $134,535 in stock By Investing.com - Investing.com Canada

Oct 22, 2024
pulisher
Oct 22, 2024

Cracking The Code: Understanding Analyst Reviews For Arcellx - Benzinga

Oct 22, 2024
pulisher
Oct 22, 2024

Arcellx, Inc. (NASDAQ:ACLX) Receives Average Rating of "Buy" from Analysts - MarketBeat

Oct 22, 2024
pulisher
Oct 22, 2024

Arcellx (NASDAQ:ACLX) Reaches New 52-Week High After Analyst Upgrade - Defense World

Oct 22, 2024
pulisher
Oct 21, 2024

Arcellx (NASDAQ:ACLX) Reaches New 12-Month High After Analyst Upgrade - MarketBeat

Oct 21, 2024
pulisher
Oct 21, 2024

Canaccord Genuity Group Increases Arcellx (NASDAQ:ACLX) Price Target to $115.00 - Defense World

Oct 21, 2024
pulisher
Oct 20, 2024

Stifel Nicolaus Increases Arcellx (NASDAQ:ACLX) Price Target to $122.00 - Defense World

Oct 20, 2024
pulisher
Oct 19, 2024

(ACLX) Trading Advice - Stock Traders Daily

Oct 19, 2024
pulisher
Oct 18, 2024

Stifel lifts Arcellx stock target, keeps buy rating on safety profile optimism - Investing.com India

Oct 18, 2024
pulisher
Oct 18, 2024

4 Analysts Assess Arcellx: What You Need To Know - Benzinga

Oct 18, 2024
pulisher
Oct 18, 2024

Arcellx (NASDAQ:ACLX) PT Raised to $122.00 - MarketBeat

Oct 18, 2024
pulisher
Oct 18, 2024

Stifel lifts Arcellx stock target, keeps buy rating on safety profile optimism By Investing.com - Investing.com South Africa

Oct 18, 2024
pulisher
Oct 17, 2024

Arcellx (NASDAQ:ACLX) PT Raised to $115.00 at Canaccord Genuity Group - MarketBeat

Oct 17, 2024
pulisher
Oct 17, 2024

Arcellx stock soars to all-time high of $88.67 amid robust growth - Investing.com Australia

Oct 17, 2024
pulisher
Oct 16, 2024

Examining the Potential Price Growth of Arcellx Inc (ACLX) - Knox Daily

Oct 16, 2024
pulisher
Oct 15, 2024

Arcellx (NASDAQ:ACLX) Reaches New 1-Year HighTime to Buy? - MarketBeat

Oct 15, 2024
pulisher
Oct 13, 2024

Arcellx, Inc. (NASDAQ:ACLX) Shares Acquired by AQR Capital Management LLC - Defense World

Oct 13, 2024
pulisher
Oct 11, 2024

12,035 Shares in Arcellx, Inc. (NASDAQ:ACLX) Purchased by SG Americas Securities LLC - MarketBeat

Oct 11, 2024
pulisher
Oct 09, 2024

Arcellx Inc (ACLX) may enjoy gains as insiders got busy in the recent days - Knox Daily

Oct 09, 2024
pulisher
Oct 09, 2024

ACLX’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle

Oct 09, 2024
pulisher
Oct 09, 2024

Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Oct 09, 2024
pulisher
Oct 08, 2024

(ACLX) Technical Data - Stock Traders Daily

Oct 08, 2024
pulisher
Oct 08, 2024

Arcellx (NASDAQ:ACLX) Shares Gap UpHere's What Happened - MarketBeat

Oct 08, 2024
pulisher
Oct 08, 2024

Redburn sees Arcellx stock gaining from innovative CAR-T platform and strong growth - Investing.com Canada

Oct 08, 2024
pulisher
Oct 08, 2024

The Manufacturers Life Insurance Company Increases Position in Arcellx, Inc. (NASDAQ:ACLX) - Defense World

Oct 08, 2024
pulisher
Oct 08, 2024

Arcellx (NASDAQ:ACLX) Earns Buy Rating from Analysts at Redburn Atlantic - MarketBeat

Oct 08, 2024
pulisher
Oct 08, 2024

The Manufacturers Life Insurance Company Boosts Stock Position in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat

Oct 08, 2024

Arcellx Inc (ACLX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
자본화:     |  볼륨(24시간):